4
3
カタログ番号 | 製品名 | 別名 | ターゲット |
---|---|---|---|
T5S1177 | Aloin B | Isobarbaloin | Others |
Aloin B (Isobarbaloin) is an isomer of aloin.1. The extract of A. vera and its active ingredient aloin cause melanin aggregation leading to skin lightening via alpha adrenergic receptor stimulation, the result opens new ... | |||
T5680 | Aloin(mixture of A&B) | MMP , IL Receptor , Antibacterial , Antifungal | |
ALOIN Inhibits Interleukin (IL)-1β-Stimulated IL-8 Production in KB Cells. | |||
T2742 | Aloin | Barbaloin,Barbalin,Aloin-A,Aloin(mixture of A&B),Barbaloin-A | Tyrosinase |
Aloin (Aloin-A)(mixture of A&B), a natural anthracycline from Aloe vera, is a tyrosinase inhibitor. | |||
T83138 | Aloinoside A | ||
Aloinoside A, an aloin isolated from Astragalus membranaceus, is the enantiomer of Aloinoside B and is a biomarker used in metabolic research. Its metabolic products by rat intestinal bacteria include aloin, isoaloin and... |
カタログ番号 | 製品名 | Species | Expression System |
---|---|---|---|
TMPK-01413 | H-2K (b) &B2M&OVA (SIINFEKL) Monomer Protein, Mouse, MHC (His & Avi) | Mouse | HEK293 Cells |
Ovalbumin (OVA) has been historically a popular source of such antigens, since OVA can induce both humoral and cellular immune responses based on well-characterised peptide epitopes. The OVA257-264 octapeptide was one of... | |||
TMPK-01416 | HLA-B*15:01&B2M&SARS-CoV-2 epitope (NQKLIANQF) Monomer Protein, Human, MHC (His & Avi), Biotinylated | Human | HEK293 Cells |
HLA-B*15:01 is strongly associated with asymptomatic infection with SARS-CoV-2 and is likely to be involved in the mechanism underlying early viral clearance. T cells from pre-pandemic individuals carrying HLA-B*15:01 we... | |||
TMPK-01412 | HLA-B*15:01&B2M&SARS-CoV-2 epitope (NQKLIANQF) Monomer Protein, Human, MHC (His & Avi) | Human | HEK293 Cells |
HLA-B*15:01 is strongly associated with asymptomatic infection with SARS-CoV-2 and is likely to be involved in the mechanism underlying early viral clearance. T cells from pre-pandemic individuals carrying HLA-B*15:01 we... |